Inherited retinal diseases; gene therapy; adeno-associated virus; CRISPR/Cas; ocular drug delivery; pharmacogenomics · Inherited retinal diseases (IRDs) constitute a large and heterogeneous group of rare genetic disorders that progressively impair visual function and often culminate in ... Inherited retinal diseases; gene therapy; adeno-associated virus; CRISPR/Cas; ocular drug delivery; pharmacogenomics · Inherited retinal diseases (IRDs) constitute a large and heterogeneous group of rare genetic disorders that progressively impair visual function and often culminate in irreversible blindness. Inherited retinal diseases (IRDs) represent a diverse group of rare, predominantly monogenic disorders characterized by progressive degeneration of photoreceptors and/or the retinal pigment epithelium, ultimately leading to irreversible visual impairment or blindness. Affecting approximately 1 in 3,000–4,000 individuals worldwide, IRDs constitute a major cause of childhood and early-onset blindness. Advances in molecular genetics, next-generation sequencing, and ocular drug delivery systems have transformed the diagnostic and therapeutic landscape of these conditions. Inherited retinal diseases (IRDs) represent one of the most genetically heterogeneous groups of human disorders. They are caused by pathogenic variants in more than 260 genes, each involved in critical aspects of photoreceptor development, function, and maintenance [11, 12]. Despite their genetic diversity, a unifying theme across IRDs is the progressive loss of rod and cone photoreceptors and/or retinal pigment epithelium (RPE) cells, leading to irreversible visual decline. Mutations in these pathways cause progressive degeneration of rods, cones, and/or RPE cells, leading to varied clinical phenotypes such as retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease, achromatopsia, Usher syndrome, and choroideremia. 2. Historical Perspective of Gene Therapy for IRDs · Until the past decade, IRDs were considered incurable. Management strategies were largely supportive, such as low-vision aids, counseling, and in rare cases, vitamin A supplementation for RP [3]. The paradigm shifted in the early 2000s, when proof-of-concept animal studies demonstrated the feasibility of adeno-associated virus (AAV)-mediated gene delivery to photoreceptors and RPE cells [4, 5]. These preclinical successes laid the foundation for clinical trials, culminating in the 2017 U.S.

Expansion of Clinical Development Cell and gene therapy technologies are being investigated across a broad range of rare diseases, including hemophilia, lysosomal storage disorders, neurological diseases, inherited retinal diseases, muscular disorders, metabolic disorders, and skin diseases. Cell and Gene Therapies in Rare Disorders market is undergoing significant transformation as advances in genetic medicine increasing clinical development activity regulatory approvals the expansion of one time therapeutic approaches create new opportunities across rare disease treatment According to DelveInsight ... Press release - ABNewswire - Cell and Gene Therapies in Rare Disorders Market to Expand as Regulatory Approvals and Pipeline Innovation Accelerate Adoption | DelveInsight - published on openPR.com * Regulatory approvals of LIBMELDY, SKYSONA, HOLOCLAR, UPSTAZA, ROCTAVIAN, and other therapies have helped establish regulatory pathways for additional cell and gene therapy programs. * Multiple companies continue to advance cell and gene therapies for hemophilia A and B, lysosomal storage disorders, neurological disorders, inherited retinal diseases, muscular disorders, metabolic diseases, and other rare conditions.

The authors of a review of 16 gene therapy trials for inherited retinal diseases explain why the pediatric evidence base remains thin and argue that individual-level, age-stratified reporting is the change most needed before CRISPR-based editing reaches children. The RPGR trials are therefore overall more mature and have a genuinely larger evidence base. The responsible framing is that dedicated, pediatric-specific dose-finding studies need to happen before a specific dose is adopted for children with achromatopsia (or with other diseases, as this applies to all gene therapy treatments discussed in the review). In this aspect, too, age-stratified trial design is essential to capture both this risk and the treatment’s efficacy. In truth, there is no single right answer to this question. On one hand, as noted in our review, gene therapy effectiveness appears to be timeframe- and VA-related, with patients who have better baseline VA showing more significant improvement. Given the progressive nature of these diseases, intervening before photoreceptor degeneration sets in could be impactful for a child’s lifespan. Even though LHON is a relatively rare condition, our review found it at the forefront of research for pediatric ocular gene therapy. Another unexpected finding was that most of the supporting evidence base for Luxturna remained distributed across smaller early-phase studies, despite its FDA approval, which would theoretically warrant larger and more stratified studies. The geographic concentration was not particularly surprising, as the ClinicalTrials.gov database is predominantly US-based, but it does have real implications for generalizability, given that genetic and phenotypic diversity in IRDs is substantial. In a review of 16 trials1, the authors below found that most studies did not stratify outcomes by age, few reported pediatric adverse events separately, and some did not report how many children were enrolled at all—leaving clinicians to counsel families and weigh procedural risk by extrapolating from adult data onto a physiologically and developmentally different patient. That extrapolation is especially consequential in young children, for whom inflammation, cataracts, or prolonged postoperative occlusion can induce amblyopia during the critical period of visual development—an independent, disease-agnostic form of vision loss that adult trials cannot detect by design.

LUXTURNA’s one-time, durable therapy addresses high unmet need in inherited retinal disease. Opportunities include broader genetic testing and treatment... Its detailed sales forecasts, competitive assessment, and regional market analysis support strategic planning, portfolio management, reimbursement decisions, and investment evaluation within the inherited retinal disease market. Key Topics Covered 1. Report Introduction 2. LUXTURNA Overview in approved indications like Leber congenital amaurosis and Retinal dystrophies 2.1. Product Detail 2.2. LUXTURNA Clinical Development 2.2.1. LUXTURNA Clinical studies 2.2.2. LUXTURNA Clinical trials information 2.2.3. Safety and efficacy 2.3. Other Developmental Activities 2.4. Product Profile 3. LUXTURNA Competitive Landscape (Marketed Therapies) 4. The report evaluates LUXTURNA's projected market size, peak sales potential, pricing strategy, reimbursement environment, and positioning within the inherited retinal disease treatment landscape. It also assesses pipeline therapies that could affect future demand, including competing gene therapies and other advanced modalities in development for Leber congenital amaurosis and retinal dystrophies. LUXTURNA's established regulatory position, durable clinical results, and first-mover advantage support its commercial outlook. Nevertheless, market expansion may be constrained by the limited eligible population, requirements for genetic confirmation, treatment-center capacity, surgical complexity, high acquisition costs, and the emergence of competing therapies. Identification of previously undiagnosed patients and broader access to genetic testing may influence future uptake. ... The LUXTURNA market forecast is developed through internal databases, primary research, secondary research, and analysis by industry experts. Sources include regulatory authority publications, clinical trial registries, company disclosures, peer-reviewed journals, trade publications, industry associations, market databases, and relevant news sources. Limited disease-modifying treatment alternatives for eligible patients · High unmet need associated with progressive vision loss · Strong clinical differentiation within ultra-rare inherited retinal diseases

The most important development ... certain rare metabolic or neuromuscular diseases, inherited retinal disorders and some cancers. Gene therapy aims to address disease at a biological level. Depending on the treatment, it may provide a working copy of a gene, silence a harmful gene, alter a genetic sequence, or equip immune cells to recognize ... The most important development is not one universal treatment, but a growing range of approaches designed for particular conditions, including inherited blood disorders, certain rare metabolic or neuromuscular diseases, inherited retinal disorders and some cancers. Gene therapy aims to address disease at a biological level. Depending on the treatment, it may provide a working copy of a gene, silence a harmful gene, alter a genetic sequence, or equip immune cells to recognize cancer. This is especially relevant to selected inherited blood disorders, where corrected blood-forming cells can continue producing healthy blood cells over time. However, the word “cure” should be used carefully because long-term outcomes continue to be studied. Free ConsultationHave questions about your own case? Gene therapy has also been developed for certain inherited retinal diseases, spinal muscular atrophy, primary immunodeficiencies, metabolic disorders and rare neurological conditions. Treatment may be given directly in the body or by modifying collected cells in a laboratory before returning them. Careful long-term follow-up is essential because benefits and delayed side effects must be monitored over time. Medically reviewed by the Acıbadem International Medical Board — August 16, 2026 · Dr. Bahadır Kaynarkaya, MD Dr. Şule Eren, MD · Gene therapy breakthroughs in 2025 are building on approved treatments for selected inherited disorders, cancers and blood diseases, while research continues to improve precision, safety and access. The latest updates in gene therapy in 2025 include continued expansion of clinical experience with approved therapies and further research into safer, more precise delivery. Gene-editing approaches for inherited blood diseases remain a major area of progress, while researchers are also studying treatments for neurological, eye, liver, muscle and immune-system disorders. A key focus is improving how genetic material reaches the right cells.